Therapeutic area intelligence for Diabetic Kidney Disease with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Mediar Therapeutics →

Assets

MTX-439 →

Recent signals(1)

ClinicalJune 30, 2026

Phase 1 Study of MTX-439 in Diabetic Kidney Disease Patients Initiated by Mediar Therapeutics

Mediar Therapeutics has initiated Phase 1 trial to evaluate the safety and pharmacokinetics of MTX-439 in healthy adults and those with diabetic kidney disease.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Diabetic Kidney Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.